When a company such as Terns Pharmaceuticals splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.

Looking at the Terns Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 2000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Terns Pharmaceuticals shares, starting with a $10,000 purchase of TERN, presented on a split-history-adjusted basis factoring in the complete Terns Pharmaceuticals stock split history.

About Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address diseases, such as non-alcoholic steatohepatitis (NASH) and obesity. Co.'s primary program is TERN-101, a liver-distributed, non-bile acid Farnesoid X Receptor (FXR) agonist that has demonstrated sustained liver FXR activation, as well as a favorable tolerability profile across multiple clinical trials. Co.'s another clinical stage program, TERN-201, is an inhibitor of Vascular Adhesion Protein-1. Co. is also evaluating the potential to co-administer TERN-201 in combination with a metabolically active NASH treatment. According to our Terns Pharmaceuticals stock split history records, Terns Pharmaceuticals has had 1 split.

Terns Pharmaceuticals Stock Split History | www.StockSplitHistory.com | Copyright © 2013 - 2024, All Rights Reserved